The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis

The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis

Background: Tocilizumab has demonstrated optimal efficacy and safety in patients with rheumatoid arthritis (RA) from clinical trials. However, the risk of hepatitis B virus reactivation (HBVr) in these patients remains uncertain because patients with underlying HBV have been excluded in phase III st...

Full description

Bibliographic Details
Main Authors: Ping-Hung Ko, Meng Hsuan Kuo, I-Ting Kao, Chen-Yi Wu, Chih-Wei Tseng, Shih-Chieh Shao
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Viruses
Subjects:
HBV reactivation
hepatitis flare-up
rheumatoid arthritis
tocilizumab
Online Access:https://www.mdpi.com/1999-4915/16/1/78

Internet

https://www.mdpi.com/1999-4915/16/1/78

Similar Items